[Baili Tianheng: Wholly-owned subsidiary plans to invest US$5 million in Connexus Therapeutics] On September 17, Baili Tianheng (688506.SH) announced that the company’s wholly-owned subsidiary Pangu Capital plans to subscribe for 3.881 million Series A preferred shares of Connexus Therapeutics for US$5 million, and will hold 7.91% of its equity after the capital increase is completed. The purpose of this transaction is to invest in Connexus and make Connexus a shareholding company of the company, broaden the company's layout in other cutting-edge technology tracks in addition to the innovative ADC drug research and development platform (HIRE-ADC platform), innovative multi-specific antibody drug research and development platform (GNC platform), specificity-enhanced bispecific antibody platform (SEBA platform) and innovative ARC (nuclear medicine) research and development platform (HIRE-ARC platform), and supplement the company's technology matrix.